Molbio Diagnostics Q1 FY27 Results: Strong Turnaround Driven by Truenat Kit Volumes
Molbio Diagnostics Ltd · Press Release · 07 Sept 2026, 3:22 pm
Molbio Diagnostics Q1 FY27 Results: Strong Turnaround Driven by Truenat Kit Volumes Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr, up sharply from ₹100.47 Cr in Q1 FY26, boosted by Truenat test kit volumes reaching 6.24 Mn units and ~₹57 Cr in deferred Q4 FY26 export orders. The company turned profitable YoY, posting an EBITDA of ₹103.68 Cr (25.20% margin) versus a ₹14.50 Cr loss, and PAT of ₹52.74 Cr (12.82% margin) versus a ₹23.94 Cr loss. Following its 17th Aug'26 listing, IPO proceeds are funding automation and a Bengaluru R&D facility.
Original exchange filing (PDF)
More announcements from Molbio Diagnostics Ltd
- Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026 · 11 Nov 2026
- Monitoring Agency Report on the utilization of proceeds raised through issuance of equity shares by way of Public Issue of the Company · 07 Nov 2026
- Audio Recording of Earnings call held on November 05,2026 for the quarter and half year ended September 30,2026. · 06 Nov 2026
- Outcome of Board meeting held on Thursday, November 05, 2026 · 06 Nov 2026
- Investor presentation · 05 Nov 2026
- Outcome of the Board Meeting · 05 Nov 2026
- Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Intimation of Earnings Conference Call on November 05, 2026, at 05:30 P.M. IST to discuss the financial performance of the Company for the quarter and half year ended September 30, 2026. · 05 Nov 2026
